Zealand Pharma signed a multi-target collaboration with Generate Biomedicines to design protein therapeutics for obesity and other metabolic diseases using Generate’s AI platform. Zealand will receive preclinical outputs and lead later clinical development, regulatory submissions and commercialization, while Generate is set to receive $30 million upfront and milestone payments tied to two initial programs.